Construction of specific magnetic resonance imaging/optical dual-modality molecular probe used for imaging angiogenesis of gastric cancer
Source abstract
Abstract
The purpose of the study was to construct specific magnetic resonance imaging (MRI)/optical dual-modality molecular probe. Tumor-bearing animal models were established. MRI/optical dual-modality molecular probe was construed by coupling polyethylene glycol (PEG)-modified nano-Fe3O4 with specific targeted cyclopeptide GX1 and near-infrared fluorescent dyes Cy5.5. MRI/optical imaging effects of the probe were observed and the feasibility of in vivo double-modality imaging was discussed. It was found that, the double-modality probe was of high stability; tumor signal of the experimental group tended to be weak after injection of the probe, but rose to a level which was close to the previous level after 18 h (p > 0.05). We successively completed the construction of an ideal MRI/optical dual-modality molecular probe. MRI/optical dual-modality molecular probe which can selectively gather in gastric cancer is expected to be a novel probe used for diagnosing gastric cancer in the early stage.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Angiogenesis and VEGF in Cancer · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Spleen and Stomach Diseases, Hospital of Traditional Chinese Medicine, Yantai, Shandong, China;
Emergency Department, Hospital of Traditional Chinese Medicine, Yantai, Shandong, China
References (30)
Show source-provided references
1. 10.3748/wjg.v21.i30.909310.3748/wjg.v21.i30.9093 ↗
2. 10.1007/s00011-015-0795-z10.1007/s00011-015-0795-z ↗
3. 10.2165/0003088-200948010-0000110.2165/0003088-200948010-00001 ↗
4. Fajardo-Ortiz D · Int J Nanomedicine · 2014 · 9 · 2627
5. 10.1073/pnas.15207059910.1073/pnas.152070599 ↗
6. 10.1007/s00418-015-1316-410.1007/s00418-015-1316-4 ↗
7. Grodent D · 2016
8. 10.2337/diabetes.54.1.15810.2337/diabetes.54.1.158 ↗
9. 10.1182/blood-2009-11-25227010.1182/blood-2009-11-252270 ↗
10. 10.1016/B978-0-12-802328-0.00006-110.1016/B978-0-12-802328-0.00006-1 ↗
11. 10.3390/toxins705168310.3390/toxins7051683 ↗
12. 10.1016/j.biomaterials.2011.09.02310.1016/j.biomaterials.2011.09.023 ↗
13. 10.1007/s11120-015-0117-x10.1007/s11120-015-0117-x ↗
14. 10.1039/C4CC10063H10.1039/C4CC10063H ↗
15. 10.1039/C4NR06441K10.1039/C4NR06441K ↗
16. 10.1039/C1CS15248C10.1039/C1CS15248C ↗
17. 10.1016/j.physb.2015.09.00510.1016/j.physb.2015.09.005 ↗
18. 10.1007/978-1-4939-2627-5_610.1007/978-1-4939-2627-5_6 ↗
19. 10.1053/j.gastro.2007.06.05610.1053/j.gastro.2007.06.056 ↗
20. 10.1016/j.micron.2015.03.00810.1016/j.micron.2015.03.008 ↗
21. 10.1002/jmri.2147710.1002/jmri.21477 ↗
22. 10.1016/j.jspr.2015.11.00410.1016/j.jspr.2015.11.004 ↗
23. 10.1002/jmri.2020310.1002/jmri.20203 ↗
24. 10.1186/s12943-015-0306-410.1186/s12943-015-0306-4 ↗
25. 10.1016/j.nucmedbio.2005.01.00510.1016/j.nucmedbio.2005.01.005 ↗
26. 10.1016/j.carbon.2015.03.04010.1016/j.carbon.2015.03.040 ↗
27. 10.1163/156856108X32006910.1163/156856108X320069 ↗
28. 10.1145/1234822.123482910.1145/1234822.1234829 ↗
29. 10.1007/s11307-010-0450-610.1007/s11307-010-0450-6 ↗
30. 10.1021/ja303056510.1021/ja3030565 ↗